{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:27:38Z","timestamp":1792801658581,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Geriatr Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Cognitive enhancers are the primary pharmacological therapy prescribed to those with dementia, comprising of memantine and the acetylcholinesterase inhibitors (AChEIs). The long-term cognitive and behavioural benefits of these medications, as well as their potential contribution to falls is currently debated, with recent Delphi studies being unable to reach consensus on whether these medications should be deprescribed. In this narrative clinical review, as part of a series on deprescribing in people at risk of falls, we explore the potential falls-related side effects experienced in people taking cognitive enhancers, alongside situations where deprescribing may be appropriate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We undertook a literature search of PubMed and Google Scholar, using terms capturing falls and cognitive enhancers, as well as consulting the British National Formulary and published Summary of Medicinal Product Characteristics. These searches informed the subsequent clinical review.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Cognitive enhancers should be subject to regular review, including confirmation of appropriate treatment indication, and occurrence of side effects in the context of falls. AChEIs, in particular, are associated with a broad range of side effects that can contribute to increased falls risk. These include bradycardia, syncope and neuromuscular effects. Where these have been identified, deprescribing should be considered, as well as alternative treatment options. Deprescribing studies have shown mixed results, likely due to considerable methodological heterogeneity. Several suggested guidelines exist to aid deprescribing decisions, many of which are highlighted in this review.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The use of cognitive enhancers should be regularly reviewed and decisions to deprescribe made on a case-by-case basis, considering both the risks and benefits of stopping these medications.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s41999-023-00821-x","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T09:02:06Z","timestamp":1688720526000},"page":"721-732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Therapeutic dilemmas: cognitive enhancers and risk of falling in older adults\u2014a clinical review"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8866-5557","authenticated-orcid":false,"given":"Gabbie E.","family":"Portlock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4685-375X","authenticated-orcid":false,"given":"Matthew D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-5602","authenticated-orcid":false,"given":"Eveline P.","family":"van Poelgeest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2619-5032","authenticated-orcid":false,"given":"Tomas James","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of\u00a0the EuGMS Task and Finish Group on FRIDs (Fall-Risk-Increasing Drugs)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"821_CR1","unstructured":"World Health Organisation (WHO). Falls\u2014fact sheet 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/falls. Accessed 11 Dec 2022"},{"key":"821_CR2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2147\/IJGM.S32651","volume":"5","author":"Y Dionyssiotis","year":"2012","unstructured":"Dionyssiotis Y (2012) Analyzing the problem of falls among older people. Int J Gen Med 5:805\u2013813. https:\/\/doi.org\/10.2147\/IJGM.S32651","journal-title":"Int J Gen Med"},{"key":"821_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000212543","volume":"28","author":"J Murphy","year":"1982","unstructured":"Murphy J, Isaacs B (1982) The post-fall syndrome. Gerontology 28:265\u2013270. https:\/\/doi.org\/10.1159\/000212543","journal-title":"Gerontology"},{"key":"821_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/CIA.S197857","volume":"14","author":"D Schoene","year":"2019","unstructured":"Schoene D, Heller C, Aung YN, Sieber CC, Kemmler W, Freiberger E (2019) A systematic review on the influence of fear of falling on quality of life in older people: is there a role for falls? Clin Interv Aging 14:701\u2013719. https:\/\/doi.org\/10.2147\/CIA.S197857","journal-title":"Clin Interv Aging"},{"key":"821_CR5","doi-asserted-by":"publisher","first-page":"e0152848","DOI":"10.1371\/JOURNAL.PONE.0152848","volume":"11","author":"MC Payette","year":"2016","unstructured":"Payette MC, B\u00e9langer C, L\u00e9veill\u00e9 V, Grenier S (2016) Fall-related psychological concerns and anxiety among community-dwelling older adults: systematic review and meta-analysis. PLoS ONE 11:e0152848. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0152848","journal-title":"PLoS ONE"},{"key":"821_CR6","unstructured":"National Institute for Health and Care Excellence (NICE) (2013) Falls in older people: assessing risk and prevention. Clinical guideline [CG161]. https:\/\/www.nice.org.uk\/guidance\/CG161\/chapter\/introduction. Accessed 25 Nov 2022"},{"key":"821_CR7","volume-title":"World Alzheimer report","author":"C Patterson","year":"2018","unstructured":"Alzheimer\u2019s Disease International, Patterson C (2018) World Alzheimer report. Alzheimer\u2019s Disease International (ADI), London"},{"key":"821_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/ageing\/27.1.7","volume":"27","author":"FE Shaw","year":"1998","unstructured":"Shaw FE, Kenny RA (1998) Can falls in patients with dementia be prevented? Age Ageing 27:7\u20139. https:\/\/doi.org\/10.1093\/ageing\/27.1.7","journal-title":"Age Ageing"},{"key":"821_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/BF03324551","volume":"16","author":"K Kallin","year":"2004","unstructured":"Kallin K, Gustafson Y, Sandman PO, Karlsson S (2004) Drugs and falls in older people in geriatric care settings. Aging Clin Exp Res 16:270\u2013276. https:\/\/doi.org\/10.1007\/BF03324551","journal-title":"Aging Clin Exp Res"},{"key":"821_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/AGEING\/AFS012","volume":"41","author":"SW Muir","year":"2012","unstructured":"Muir SW, Gopaul K, Montero Odasso MM (2012) The role of cognitive impairment in fall risk among older adults: a systematic review and meta-analysis. Age Ageing 41:299\u2013308. https:\/\/doi.org\/10.1093\/AGEING\/AFS012","journal-title":"Age Ageing"},{"key":"821_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/geronj\/42.4.412","volume":"42","author":"JC Morris","year":"1987","unstructured":"Morris JC, Rubin EH, Morris EJ, Mandep SA (1987) Senile dementia of the Alzheimer\u2019s type: an important risk factor for serious falls. J Gerontol 42:412\u2013417","journal-title":"J Gerontol"},{"key":"821_CR12","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00702-007-0741-5","volume":"114","author":"FE Shaw","year":"2007","unstructured":"Shaw FE (2007) Prevention of falls in older people with dementia. J Neural Transm 114:1259\u20131264. https:\/\/doi.org\/10.1007\/s00702-007-0741-5","journal-title":"J Neural Transm"},{"key":"821_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000017108","volume":"10","author":"CG Ballard","year":"1999","unstructured":"Ballard CG, Shaw F, Lowery K, McKeith I, Kenny R (1999) The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 10:97\u2013103. https:\/\/doi.org\/10.1159\/000017108","journal-title":"Dement Geriatr Cogn Disord"},{"key":"821_CR14","doi-asserted-by":"publisher","first-page":"e006434","DOI":"10.1136\/BMJOPEN-2014-006434\/-\/DC1","volume":"4","author":"KHO Deane","year":"2015","unstructured":"Deane KHO, Flaherty H, Daley DJ, Pascoe R, Penhale B, Clarke CE et al (2015) Priority setting partnership to identify the top 10 research priorities for the management of Parkinson\u2019s disease. BMJ Open 4:e006434. https:\/\/doi.org\/10.1136\/BMJOPEN-2014-006434\/-\/DC1","journal-title":"BMJ Open"},{"key":"821_CR15","doi-asserted-by":"publisher","first-page":"906274","DOI":"10.1155\/2013\/906274","volume":"2013","author":"NE Allen","year":"2013","unstructured":"Allen NE, Schwarzel AK, Canning CG (2013) Recurrent falls in Parkinson\u2019s disease: a systematic review. Parkinsons Dis 2013:906274. https:\/\/doi.org\/10.1155\/2013\/906274","journal-title":"Parkinsons Dis"},{"key":"821_CR16","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1002\/MDS.23932","volume":"26","author":"A Yarnall","year":"2011","unstructured":"Yarnall A, Rochester L, Burn DJ (2011) The interplay of cholinergic function, attention, and falls in Parkinson\u2019s disease. Mov Disord 26:2496\u20132503. https:\/\/doi.org\/10.1002\/MDS.23932","journal-title":"Mov Disord"},{"key":"821_CR17","unstructured":"National Institute for Health and Care Excellence (NICE) (2018) Dementia: assessment, management and support for people living with dementia and their carers. NICE guideline [NG97]. https:\/\/www.nice.org.uk\/guidance\/ng97. Acessed 11 Dec 2022"},{"key":"821_CR18","doi-asserted-by":"publisher","first-page":"CD01190","DOI":"10.1002\/14651858.CD001190.PUB3","volume":"6","author":"JS Birks","year":"2018","unstructured":"Birks JS, Harvey RJ (2018) Donepezil for dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev 6:CD01190. https:\/\/doi.org\/10.1002\/14651858.CD001190.PUB3","journal-title":"Cochrane Database Syst Rev"},{"key":"821_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001191.PUB4","author":"JS Birks","year":"2015","unstructured":"Birks JS, Chong LY, Grimley EJ (2015) Rivastigmine for Alzheimer\u2019s disease. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD001191.PUB4","journal-title":"Cochrane Database Syst Rev"},{"key":"821_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001747","author":"JT Olin","year":"2002","unstructured":"Olin JT, Schneider L (2002) Galantamine for Alzheimer\u2019s disease. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD001747","journal-title":"Cochrane Database Syst Rev"},{"key":"821_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD003154.PUB6\/MEDIA\/CDSR\/CD003154\/IMAGE_N\/NCD003154-CMP-008-07.PNG","volume":"2019","author":"R McShane","year":"2019","unstructured":"McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE et al (2019) Memantine for dementia. Cochrane Database Syst Rev 2019:1\u2013446. https:\/\/doi.org\/10.1002\/14651858.CD003154.PUB6\/MEDIA\/CDSR\/CD003154\/IMAGE_N\/NCD003154-CMP-008-07.PNG","journal-title":"Cochrane Database Syst Rev"},{"key":"821_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2217\/1745509X.1.1.7","volume":"1","author":"B Seltzer","year":"2005","unstructured":"Seltzer B (2005) Donepezil in the treatment of dementia. Expert Opin Drug Metab Toxicol 1:7\u201317. https:\/\/doi.org\/10.2217\/1745509X.1.1.7","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"821_CR23","unstructured":"National Institute for Health and Care Excellence (NICE) (2018) Rivastigmine. British National Formulary. https:\/\/bnf.nice.org.uk\/drugs\/rivastigmine\/. Accessed 30 May 2022"},{"key":"821_CR24","unstructured":"National Institute for Health and Care Excellence (NICE) (2018) Memantine hydrochloride. British National Formulary (BNF). https:\/\/bnf.nice.org.uk\/drugs\/memantine-hydrochloride\/. Accessed 18 Jan 2023"},{"key":"821_CR25","unstructured":"National Institute for Health and Care Excellence (NICE) (2018) Donepezil hydrochloride. British National Formulary (BNF). https:\/\/bnf.nice.org.uk\/drugs\/donepezil-hydrochloride\/. Accessed 18 Jan 2023"},{"key":"821_CR26","unstructured":"National Institute for Health and Care Excellence (NICE) (2018) Galantamine. British National Formulary (BNF). https:\/\/bnf.nice.org.uk\/drugs\/galantamine\/. Accessed 18 Jan 2023"},{"key":"821_CR27","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/JNNP-2014-308764","volume":"86","author":"G Pagano","year":"2015","unstructured":"Pagano G, Rengo G, Pasqualetti G, Femminella GD, Monzani F, Ferrara N et al (2015) Cholinesterase inhibitors for Parkinson\u2019s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 86:767\u2013773. https:\/\/doi.org\/10.1136\/JNNP-2014-308764","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"821_CR28","first-page":"557","volume":"169","author":"KL Lanct\u00f4t","year":"2003","unstructured":"Lanct\u00f4t KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM et al (2003) Efficacy and safety of cholinesterase inhibitors in Alzheimer\u2019s disease: a meta-analysis. CMAJ Can Med Assoc J 169:557\u2013664.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC191283\/","journal-title":"CMAJ Can Med Assoc J"},{"key":"821_CR29","doi-asserted-by":"publisher","first-page":"CD06504","DOI":"10.1002\/14651858.CD006504.PUB2\/MEDIA\/CDSR\/CD006504\/IMAGE_N\/NCD006504-CMP-005-10.PNG","volume":"2012","author":"M Rolinski","year":"2012","unstructured":"Rolinski M, Fox C, Maidment I, Mcshane R (2012) Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson\u2019s disease dementia and cognitive impairment in Parkinson\u2019s disease. Cochrane Database of Syst Rev 2012:CD06504. https:\/\/doi.org\/10.1002\/14651858.CD006504.PUB2\/MEDIA\/CDSR\/CD006504\/IMAGE_N\/NCD006504-CMP-005-10.PNG","journal-title":"Cochrane Database of Syst Rev"},{"key":"821_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/0891988704267463","volume":"17","author":"D Aarsland","year":"2004","unstructured":"Aarsland D, Mosimann UP, McKeith IG (2004) Role of cholinesterase inhibitors in Parkinson\u2019s disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 17:164\u2013171. https:\/\/doi.org\/10.1177\/0891988704267463","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"821_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/0269881116680924","volume":"31","author":"JT O\u2019Brien","year":"2017","unstructured":"O\u2019Brien JT, Holmes C, Jones M, Jones R, Livingston G, McKeith I et al (2017) Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol 31:147\u2013168. https:\/\/doi.org\/10.1177\/0269881116680924","journal-title":"J Psychopharmacol"},{"key":"821_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013306.PUB2","author":"CE Battle","year":"2021","unstructured":"Battle CE, Abdul-Rahim AH, Shenkin SD, Hewitt J, Quinn TJ (2021) Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD013306.PUB2","journal-title":"Cochrane Database Syst Rev"},{"key":"821_CR33","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5694\/MJA2.50015","volume":"210","author":"E Reeve","year":"2019","unstructured":"Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin PJ et al (2019) Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Med J Aust 210:174\u2013179. https:\/\/doi.org\/10.5694\/MJA2.50015","journal-title":"Med J Aust"},{"key":"821_CR34","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/alz.12105","volume":"16","author":"Z Ismail","year":"2020","unstructured":"Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R et al (2020) Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. Alzheimer\u2019s Dement 16:1182\u20131195. https:\/\/doi.org\/10.1002\/alz.12105","journal-title":"Alzheimer\u2019s Dement"},{"key":"821_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009132.PUB2","author":"TC Russ","year":"2012","unstructured":"Russ TC, Morling JR (2012) Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD009132.PUB2","journal-title":"Cochrane Database Syst Rev"},{"key":"821_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/1179573520907397","author":"KG Yiannopoulou","year":"2020","unstructured":"Yiannopoulou KG, Papageorgiou SG (2020) Current and future treatments in alzheimer disease: an update. J Cent Nerv Syst Dis. https:\/\/doi.org\/10.1177\/1179573520907397","journal-title":"J Cent Nerv Syst Dis"},{"key":"821_CR37","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/S40266-015-0266-9","volume":"32","author":"JS Buckley","year":"2015","unstructured":"Buckley JS, Salpeter SR (2015) A risk-benefit assessment of dementia medications: systematic review of the evidence. Drugs Aging 32:453\u2013467. https:\/\/doi.org\/10.1007\/S40266-015-0266-9","journal-title":"Drugs Aging"},{"key":"821_CR38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1586\/14737175.5.5.563","volume":"5","author":"AK Desai","year":"2005","unstructured":"Desai AK, Grossberg GT (2005) Rivastigmine for Alzheimer\u2019s disease. Expert Rev Neurother 5:563\u2013580. https:\/\/doi.org\/10.1586\/14737175.5.5.563","journal-title":"Expert Rev Neurother"},{"key":"821_CR39","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.14R01654","author":"CH Sadowsky","year":"2014","unstructured":"Sadowsky CH, Micca JL, Grossberg GT, Velting DM (2014) Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer\u2019s disease and Parkinson\u2019s disease dementia. Prim Care Companion CNS Disord. https:\/\/doi.org\/10.4088\/PCC.14R01654","journal-title":"Prim Care Companion CNS Disord"},{"key":"821_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2165\/11592230-000000000-00000","volume":"25","author":"J Greenspoon","year":"2011","unstructured":"Greenspoon J, Herrmann N, Adam DN (2011) Transdermal rivastigmine: management of cutaneous adverse events and review of the literature. CNS Drugs 25:575\u2013583. https:\/\/doi.org\/10.2165\/11592230-000000000-00000","journal-title":"CNS Drugs"},{"key":"821_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/1570159X11311030006","volume":"11","author":"MB Colovic","year":"2013","unstructured":"Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM (2013) Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol 11:315\u2013335. https:\/\/doi.org\/10.2174\/1570159X11311030006","journal-title":"Curr Neuropharmacol"},{"key":"821_CR42","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/J.ETAP.2004.12.048","volume":"19","author":"C Pope","year":"2005","unstructured":"Pope C, Karanth S, Liu J (2005) Pharmacology and toxicology of cholinesterase inhibitors: uses and misuses of a common mechanism of action. Environ Toxicol Pharmacol 19:433\u2013446. https:\/\/doi.org\/10.1016\/J.ETAP.2004.12.048","journal-title":"Environ Toxicol Pharmacol"},{"key":"821_CR43","unstructured":"National Institute for Health and Care Excellence (NICE) (2018) Galantamine|hepatic impairment. British National Formulary (BNF). https:\/\/bnf.nice.org.uk\/drugs\/galantamine\/#hepatic-impairment. Accessed 11 Dec 2022"},{"key":"821_CR44","unstructured":"National Institute for Health and Care Excellence (NICE) (2018) Memantine hydrochloride|renal impairment. British National Formulary (BNF). https:\/\/bnf.nice.org.uk\/drugs\/memantine-hydrochloride\/#renal-impairment. Accessed 11 Dec 2022"},{"key":"821_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/J.SEIZURE.2009.11.005","volume":"19","author":"E Kumlien","year":"2010","unstructured":"Kumlien E, Lundberg PO (2010) Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. Seizure 19:69\u201373. https:\/\/doi.org\/10.1016\/J.SEIZURE.2009.11.005","journal-title":"Seizure"},{"key":"821_CR46","doi-asserted-by":"publisher","first-page":"344","DOI":"10.4103\/0972-2327.179971","volume":"19","author":"P Marimuthu","year":"2016","unstructured":"Marimuthu P, Varadarajan S, Krishnan M, Shanmugam S, Kunjuraman GR, Ravinder J et al (2016) Evaluating the efficacy of memantine on improving cognitive functions in epileptic patients receiving anti-epileptic drugs: a double-blind placebo-controlled clinical trial (phase IIIb pilot study). Ann Indian Acad Neurol 19:344. https:\/\/doi.org\/10.4103\/0972-2327.179971","journal-title":"Ann Indian Acad Neurol"},{"key":"821_CR47","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2165\/00023210-200317130-00002\/FIGURES\/TAB2","volume":"17","author":"D Bentu\u00e9-Ferrer","year":"2003","unstructured":"Bentu\u00e9-Ferrer D, Tribut O, Polard E, Allain H (2003) Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 17:947\u2013963. https:\/\/doi.org\/10.2165\/00023210-200317130-00002\/FIGURES\/TAB2","journal-title":"CNS Drugs"},{"key":"821_CR48","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2165\/00003495-200060050-00008","volume":"60","author":"LJ Scott","year":"2000","unstructured":"Scott LJ, Goa KL (2000) Galantamine: a review of its use in Alzheimer\u2019s disease. Drugs 60:1095\u20131122. https:\/\/doi.org\/10.2165\/00003495-200060050-00008","journal-title":"Drugs"},{"key":"821_CR49","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1111\/jgs.16710","volume":"68","author":"JA Watt","year":"2020","unstructured":"Watt JA, Campitelli MPHMA, Maxwell CJ, Guan J, Maclagan LC, Gomes T et al (2020) Fall-related hospitalizations in nursing home residents co-prescribed a cholinesterase inhibitor and beta-blocker. J Am Geriatr Soc 68:2516\u20132524. https:\/\/doi.org\/10.1111\/jgs.16710","journal-title":"J Am Geriatr Soc"},{"key":"821_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2021.584667","author":"T Elliott","year":"2021","unstructured":"Elliott T, Eckmann L, Moga DC (2021) Case report: the complexities of managing medications and the importance of deprescribing anticholinergics in older adults. Front Pharmacol. https:\/\/doi.org\/10.3389\/FPHAR.2021.584667","journal-title":"Front Pharmacol"},{"key":"821_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/157015908783769671","volume":"6","author":"C Parsons","year":"2008","unstructured":"Parsons C, Rammes G, Danysz W (2008) Pharmacodynamics of memantine: an update. Curr Neuropharmacol 6:55\u201378. https:\/\/doi.org\/10.2174\/157015908783769671","journal-title":"Curr Neuropharmacol"},{"key":"821_CR52","first-page":"91","volume":"43","author":"J Kornhuber","year":"1994","unstructured":"Kornhuber J, Weller M, Schoppmeyer K (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm 43:91\u2013104","journal-title":"J Neural Transm"},{"key":"821_CR53","unstructured":"Electronic Medicines Compendium (EMC) (2022) https:\/\/www.medicines.org.uk\/emc#gref. Accessed 30 Jan 2023"},{"key":"821_CR54","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3233\/JAD-210524","volume":"82","author":"K Sato","year":"2021","unstructured":"Sato K, Mano T, Iwata A, Toda T (2021) Safety of memantine in combination with potentially interactive drugs in the real world: a pharmacovigilance study using the japanese adverse drug event report (JADER) database. J Alzheimers Dis 82:1333\u20131344. https:\/\/doi.org\/10.3233\/JAD-210524","journal-title":"J Alzheimers Dis"},{"key":"821_CR55","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2165\/00002512-200522120-00003","volume":"22","author":"DR Staskin","year":"2005","unstructured":"Staskin DR (2005) Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging 22:1013\u20131028. https:\/\/doi.org\/10.2165\/00002512-200522120-00003","journal-title":"Drugs Aging"},{"key":"821_CR56","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/JGS.18066","volume":"71","author":"KR Gromek","year":"2022","unstructured":"Gromek KR, Thorpe CT, Aspinall SL, Hanson LC, Niznik JD (2022) Anticholinergic co-prescribing in nursing home residents using cholinesterase inhibitors: potential deprescribing cascade. J Am Geriatr Soc 71:77\u201388. https:\/\/doi.org\/10.1111\/JGS.18066","journal-title":"J Am Geriatr Soc"},{"key":"821_CR57","doi-asserted-by":"publisher","first-page":"e01008","DOI":"10.1002\/PRP2.1008","volume":"10","author":"AS Doherty","year":"2022","unstructured":"Doherty AS, Shahid F, Moriarty F, Boland F, Clyne B, Dreischulte T et al (2022) Prescribing cascades in community-dwelling adults: a systematic review. Pharmacol Res Perspect 10:e01008. https:\/\/doi.org\/10.1002\/PRP2.1008","journal-title":"Pharmacol Res Perspect"},{"key":"821_CR58","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/ARCHINTE.165.7.808","volume":"165","author":"SS Gill","year":"2005","unstructured":"Gill SS, Mamdani M, Naglie G, Streiner DL, Bronskill SE, Kopp A et al (2005) A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 165:808\u2013813. https:\/\/doi.org\/10.1001\/ARCHINTE.165.7.808","journal-title":"Arch Intern Med"},{"key":"821_CR59","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1185\/03007995.2016.1149806","volume":"32","author":"A Wagg","year":"2016","unstructured":"Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T (2016) Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin 32:621\u2013638. https:\/\/doi.org\/10.1185\/03007995.2016.1149806","journal-title":"Curr Med Res Opin"},{"key":"821_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13643-020-01296-8\/TABLES\/4","volume":"9","author":"MS Brueckle","year":"2020","unstructured":"Brueckle MS, Thomas ET, Seide SE, Pilz M, Gonzalez-Gonzalez AI, Nguyen TS et al (2020) Adverse drug reactions associated with amitriptyline\u2014protocol for a systematic multiple-indication review and meta-analysis. Syst Rev 9:1\u20138. https:\/\/doi.org\/10.1186\/S13643-020-01296-8\/TABLES\/4","journal-title":"Syst Rev"},{"key":"821_CR61","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/13607860500431652","volume":"10","author":"B Woods","year":"2007","unstructured":"Woods B, Thorgrimsen L, Spector A, Royan L, Orrell M (2007) Improved quality of life and cognitive stimulation therapy in dementia. Aging Ment Health 10:219\u2013226. https:\/\/doi.org\/10.1080\/13607860500431652","journal-title":"Aging Ment Health"},{"key":"821_CR62","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1192\/BJP.183.3.248","volume":"183","author":"A Spector","year":"2003","unstructured":"Spector A, Thorgrimsen L, Woods B, Royan L, Davies S, Butterworth M et al (2003) Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. Br J Psychiatry 183:248\u2013254. https:\/\/doi.org\/10.1192\/BJP.183.3.248","journal-title":"Br J Psychiatry"},{"key":"821_CR63","unstructured":"Spector A, Orrell M, Woods B, Fisher E. Cognitive stimulation therapy 2023. http:\/\/www.cstdementia.com\/. Accessed 28 Dec 2022"},{"key":"821_CR64","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/GPS.3823","volume":"28","author":"E Aguirre","year":"2013","unstructured":"Aguirre E, Hoare Z, Streater A, Spector A, Woods B, Hoe J et al (2013) Cognitive stimulation therapy (CST) for people with dementia\u2014who benefits most? Int J Geriatr Psychiatry 28:284\u2013290. https:\/\/doi.org\/10.1002\/GPS.3823","journal-title":"Int J Geriatr Psychiatry"},{"key":"821_CR65","doi-asserted-by":"publisher","unstructured":"Adeyinka A, Kondamudi NP (2022) Cholinergic crisis. StatPearls. https:\/\/doi.org\/10.1007\/978-3-211-79280-3_237","DOI":"10.1007\/978-3-211-79280-3_237"},{"key":"821_CR66","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/J.1532-5415.2011.03450.X","volume":"59","author":"DH Kim","year":"2011","unstructured":"Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD (2011) Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc 59:1019\u20131031. https:\/\/doi.org\/10.1111\/J.1532-5415.2011.03450.X","journal-title":"J Am Geriatr Soc"},{"key":"821_CR67","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/S11556-011-0078-9\/METRICS","volume":"8","author":"E Freiberger","year":"2011","unstructured":"Freiberger E, de Vreede P (2011) Falls recall-limitations of the most used inclusion criteria. Eur Rev Aging Phys Act 8:105\u2013108. https:\/\/doi.org\/10.1007\/S11556-011-0078-9\/METRICS","journal-title":"Eur Rev Aging Phys Act"},{"key":"821_CR68","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2147\/TCRM.S323387","volume":"17","author":"S Ruangritchankul","year":"2021","unstructured":"Ruangritchankul S, Chantharit P, Srisuma S, Gray LC (2021) Adverse drug reactions of acetylcholinesterase inhibitors in older people living with dementia: a comprehensive literature review. Ther Clin Risk Manag 17:927\u2013949. https:\/\/doi.org\/10.2147\/TCRM.S323387","journal-title":"Ther Clin Risk Manag"},{"key":"821_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005593","author":"J Birks","year":"2006","unstructured":"Birks J (2006) Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD005593","journal-title":"Cochrane Database Syst Rev"},{"key":"821_CR70","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","volume":"6","author":"H Kavirajan","year":"2007","unstructured":"Kavirajan H, Schneider LS (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 6:782\u2013792. https:\/\/doi.org\/10.1016\/S1474-4422(07)70195-3","journal-title":"Lancet Neurol"},{"key":"821_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/AGEING\/AFAC205","volume":"51","author":"M Montero-Odasso","year":"2022","unstructured":"Montero-Odasso M, van der Velde N, Martin FC, Petrovic M, Tan MP, Ryg J et al (2022) World guidelines for falls prevention and management for older adults: a global initiative. Age Ageing 51:1\u201336. https:\/\/doi.org\/10.1093\/AGEING\/AFAC205","journal-title":"Age Ageing"},{"key":"821_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/J.1365-2125.2004.01848.X","volume":"58","author":"S Jackson","year":"2004","unstructured":"Jackson S, Ham RJ, Wilkinson D (2004) The safety and tolerability of donepezil in patients with Alzheimer\u2019s disease. Br J Clin Pharmacol 58:1\u20138. https:\/\/doi.org\/10.1111\/J.1365-2125.2004.01848.X","journal-title":"Br J Clin Pharmacol"},{"key":"821_CR73","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/GPS.2506","volume":"25","author":"V Larsson","year":"2010","unstructured":"Larsson V, Aarsland D, Ballard C, Minthon L, Londos E (2010) The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson\u2019s disease dementia. Int J Geriatr Psychiatry 25:1030\u20131038. https:\/\/doi.org\/10.1002\/GPS.2506","journal-title":"Int J Geriatr Psychiatry"},{"key":"821_CR74","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1185\/030079905X56565","volume":"21","author":"R Bullock","year":"2005","unstructured":"Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G et al (2005) Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer\u2019s disease over a 2-year period. Curr Med Res Opin 21:1317\u20131327. https:\/\/doi.org\/10.1185\/030079905X56565","journal-title":"Curr Med Res Opin"},{"key":"821_CR75","doi-asserted-by":"publisher","first-page":"111154","DOI":"10.1016\/J.EXGER.2020.111154","volume":"143","author":"H Blain","year":"2021","unstructured":"Blain H, Gamon L, Aliaga B, Soriteau L, Raffort N, Miot S et al (2021) Self-reported fatigue: a significant risk factor for falling in older women and men. Exp Gerontol 143:111154. https:\/\/doi.org\/10.1016\/J.EXGER.2020.111154","journal-title":"Exp Gerontol"},{"key":"821_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/GERONI\/IGAA061","volume":"5","author":"SW Renner","year":"2021","unstructured":"Renner SW, Cauley JA, Brown PJ, Boudreau RM, Bear TM, Blackwell T et al (2021) Higher fatigue prospectively increases the risk of falls in older men. Innov Aging 5:1\u20138. https:\/\/doi.org\/10.1093\/GERONI\/IGAA061","journal-title":"Innov Aging"},{"key":"821_CR77","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5698\/1535-7511-12.5.184","volume":"12","author":"D Pandis","year":"2012","unstructured":"Pandis D, Scarmeas N (2012) Seizures in Alzheimer disease: clinical and epidemiological data. Epilepsy Curr 12:184\u2013187. https:\/\/doi.org\/10.5698\/1535-7511-12.5.184","journal-title":"Epilepsy Curr"},{"key":"821_CR78","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/J.1755-5949.2011.00251.X","volume":"18","author":"D Friedman","year":"2012","unstructured":"Friedman D, Honig LS, Scarmeas N (2012) Seizures and epilepsy in Alzheimer\u2019s disease. CNS Neurosci Ther 18:285. https:\/\/doi.org\/10.1111\/J.1755-5949.2011.00251.X","journal-title":"CNS Neurosci Ther"},{"key":"821_CR79","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/1756285611417920","volume":"4","author":"CM Eddy","year":"2011","unstructured":"Eddy CM, Rickards HE, Cavanna AE (2011) The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord 4:385\u2013407. https:\/\/doi.org\/10.1177\/1756285611417920","journal-title":"Ther Adv Neurol Disord"},{"key":"821_CR80","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/FNEUR.2012.00073","volume":"3","author":"J Cerejeira","year":"2012","unstructured":"Cerejeira J, Lagarto L, Mukaetova-Ladinska EB (2012) Behavioral and psychological symptoms of dementia. Front Neurol 3:73. https:\/\/doi.org\/10.3389\/FNEUR.2012.00073","journal-title":"Front Neurol"},{"key":"821_CR81","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/11530300-000000000-00000","volume":"24","author":"A Pariente","year":"2010","unstructured":"Pariente A, Sanctussy DJR, Miremont-Salam\u00e9 G, Moore N, Haramburu F, Fourrier-R\u00e9glat A (2010) Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting. CNS Drugs 24:55\u201363. https:\/\/doi.org\/10.2165\/11530300-000000000-00000","journal-title":"CNS Drugs"},{"key":"821_CR82","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000074281","volume":"17","author":"ZJ Wynn","year":"2004","unstructured":"Wynn ZJ, Cummings JL (2004) Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 17:100\u2013108. https:\/\/doi.org\/10.1159\/000074281","journal-title":"Dement Geriatr Cogn Disord"},{"key":"821_CR83","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/J.1755-5949.2010.00166.X","volume":"17","author":"T Van Laar","year":"2011","unstructured":"Van Laar T, De Deyn PP, Aarsland D, Barone P, Galvin JE (2011) Effects of cholinesterase inhibitors in Parkinson\u2019s disease dementia: a review of clinical data. CNS Neurosci Ther 17:428\u2013441. https:\/\/doi.org\/10.1111\/J.1755-5949.2010.00166.X","journal-title":"CNS Neurosci Ther"},{"key":"821_CR84","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/JNNP.2008.152579","volume":"8","author":"W Poewe","year":"2008","unstructured":"Poewe W (2008) When a Parkinson\u2019s disease patient starts to hallucinate. Pract Neurol 8:238\u2013241. https:\/\/doi.org\/10.1136\/JNNP.2008.152579","journal-title":"Pract Neurol"},{"key":"821_CR85","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/00002826-200305000-00004","volume":"26","author":"A Villarejo","year":"2003","unstructured":"Villarejo A, Camacho A, Garc\u00eda-Ramos R, Moreno T, Penas M, Juntas R et al (2003) Cholinergic-dopaminergic imbalance in Pisa syndrome. Clin Neuropharmacol 26:119\u2013121. https:\/\/doi.org\/10.1097\/00002826-200305000-00004","journal-title":"Clin Neuropharmacol"},{"key":"821_CR86","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/J.1532-5415.2007.01143.X","volume":"55","author":"JM Starr","year":"2007","unstructured":"Starr JM (2007) Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer\u2019s disease. J Am Geriatr Soc 55:800\u2013801. https:\/\/doi.org\/10.1111\/J.1532-5415.2007.01143.X","journal-title":"J Am Geriatr Soc"},{"key":"821_CR87","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/14740338.2018.1397625","volume":"17","author":"E Reeve","year":"2017","unstructured":"Reeve E, Moriarty F, Nahas R, Turner JP, Kouladjian O\u2019Donnell L, Hilmer SN (2017) A narrative review of the safety concerns of deprescribing in older adults and strategies to mitigate potential harms. Expert Opin Drug Saf 17:39\u201349. https:\/\/doi.org\/10.1080\/14740338.2018.1397625","journal-title":"Expert Opin Drug Saf"},{"key":"821_CR88","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/ARCHNEUR.58.3.427","volume":"58","author":"RS Doody","year":"2001","unstructured":"Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD (2001) Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58:427\u2013433. https:\/\/doi.org\/10.1001\/ARCHNEUR.58.3.427","journal-title":"Arch Neurol"},{"key":"821_CR89","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1111\/JGS.15614","volume":"66","author":"HM Roitto","year":"2018","unstructured":"Roitto HM, Kautiainen H, \u00d6hman H, Savikko N, Strandberg TE, Raivio M et al (2018) Relationship of neuropsychiatric symptoms with falls in Alzheimer\u2019s disease\u2014does exercise modify the risk? J Am Geriatr Soc 66:2377\u20132381. https:\/\/doi.org\/10.1111\/JGS.15614","journal-title":"J Am Geriatr Soc"},{"key":"821_CR90","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/J.JAMDA.2020.04.003","volume":"21","author":"HM Roitto","year":"2020","unstructured":"Roitto HM, \u00d6hman H, Salminen K, Kautiainen H, Laurila J, Pitk\u00e4l\u00e4 KH (2020) Neuropsychiatric symptoms as predictors of falls in long-term care residents with cognitive impairment. J Am Med Dir Assoc 21:1243\u20131248. https:\/\/doi.org\/10.1016\/J.JAMDA.2020.04.003","journal-title":"J Am Med Dir Assoc"},{"key":"821_CR91","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1080\/03007995.2018.1490255","volume":"34","author":"G-A Perri","year":"2018","unstructured":"Perri G-A, Liao P (2018) A palliative care perspective on deprescribing cholinesterase inhibitors in Alzheimer\u2019s disease. Curr Med Res Opin 34:1695\u20131697. https:\/\/doi.org\/10.1080\/03007995.2018.1490255","journal-title":"Curr Med Res Opin"},{"key":"821_CR92","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1447-0594.2009.00519.x","volume":"9","author":"YT Kwak","year":"2009","unstructured":"Kwak YT, Han I-W, Suk S-H, Koo M-S (2009) Two cases of discontinuation syndrome following cessation of memantine. Geriatr Gerontol Int 9:203\u2013205. https:\/\/doi.org\/10.1111\/j.1447-0594.2009.00519.x","journal-title":"Geriatr Gerontol Int"},{"key":"821_CR93","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13311-021-01171-x","volume":"19","author":"N Weisbrod","year":"2022","unstructured":"Weisbrod N (2022) Primary palliative care in dementia. Neurotherapeutics 19:143\u2013151. https:\/\/doi.org\/10.1007\/s13311-021-01171-x","journal-title":"Neurotherapeutics"},{"key":"821_CR94","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/JGS.16241","volume":"68","author":"JD Niznik","year":"2020","unstructured":"Niznik JD, Zhao X, He M, Aspinall SL, Hanlon JT, Hanson LC et al (2020) Risk for health events after deprescribing acetylcholinesterase inhibitors in nursing home residents with severe dementia. J Am Geriatr Soc 68:699\u2013707. https:\/\/doi.org\/10.1111\/JGS.16241","journal-title":"J Am Geriatr Soc"},{"key":"821_CR95","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.clinthera.2021.05.010","volume":"43","author":"LR Moo","year":"2021","unstructured":"Moo LR, Martinez E, Padala K, Dunay MA, Scali RR, Chen S et al (2021) Unexpected findings during double-blind discontinuation of acetylcholinesterase inhibitor medications. Clin Ther 43:942\u2013952. https:\/\/doi.org\/10.1016\/j.clinthera.2021.05.010","journal-title":"Clin Ther"},{"key":"821_CR96","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/J.JAGP.2017.09.027","volume":"26","author":"BN Renn","year":"2018","unstructured":"Renn BN, Asghar-Ali AA, Thielke S, Catic A, Martini SR, Mitchell BG et al (2018) A systematic review of practice guidelines and recommendations for discontinuation of cholinesterase inhibitors in dementia. Am J Geriatr Psychiatry 26:134\u2013147. https:\/\/doi.org\/10.1016\/J.JAGP.2017.09.027","journal-title":"Am J Geriatr Psychiatry"},{"key":"821_CR97","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/S12883-021-02430-2","volume":"21","author":"S Neumann","year":"2021","unstructured":"Neumann S, Taylor J, Bamford A, Metcalfe C, Gaunt DM, Whone A et al (2021) Cholinesterase inhibitor to prevent falls in Parkinson\u2019s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson\u2019s disease. BMC Neurol 21:422. https:\/\/doi.org\/10.1186\/S12883-021-02430-2","journal-title":"BMC Neurol"}],"container-title":["European Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-023-00821-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41999-023-00821-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-023-00821-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T16:03:27Z","timestamp":1692806607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41999-023-00821-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":97,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1007\/s41999-023-00821-x","relation":{},"ISSN":["1878-7657"],"issn-type":[{"value":"1878-7657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]},"assertion":[{"value":"9 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GEP, MDS, and EPP have no relevant financial or non-financial interests to disclose. TW is Research and Medical Director of The Research Institute for the Care of Older People (RICE), which runs a mixture of commercial and non-commercial research activity. Commercial research projects run in the Institute have been funded by: Roche, Biogen, Janssen, AC Immune, Novo Nordisk, and Julius Clinical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent is not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}